Adicet's Prula-cel Shows 50% Complete Renal Response in Lupus Nephritis, Pivotal Study Planned
ACET sits 66% above its 52-week low of $6.01 on elevated volume (5.4× avg).
Summary
Adicet Bio reported positive Phase 1 data for prula-cel in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN). At 12 months, 50% of evaluable LN patients achieved complete renal response and 54% achieved DORIS remission, with responses ongoing up to 21 months. Safety was favorable: no CRS above Grade 2, no ICANS, no IEC-HS, supporting outpatient dosing. The company has aligned with the FDA on a single-arm pivotal study in LN and plans to initiate start-up activities in Q4 2026, with potential expansion to non-renal SLE. This is the first disclosure of these efficacy results and the pivotal study design, following the 8-K on September 1 that announced completion of the last patient visit and expected topline data in September. The data de-risks the program and sets a clear regulatory path, a major catalyst for a company with a market cap around $84 million.
Updates
· SEC 8-K — The 8-K includes the full press release and corporate presentation, and notes the company will host a webcast at 8:00 a.m. ET today.
At the time of this announcement, ACET was trading at $9.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.4M. The 52-week trading range was $6.01 to $17.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.